Roche's taspoglutide gins blockbuster diabetes data in PhIII

Roche (NASDAQ: RHHBY) took another big stride today in its long march toward a regulatory filing for the likely diabetes blockbuster taspoglutide. The pharma giant said that the experimental medicine produced promising Phase III data, proving significantly superior to a placebo. Fresh evidence of safety and efficacy is steadily boosting analysts' estimates of likely sales. "We believe taspoglutide has the potential to develop substantial sales over time, which we believe could reach a peak of 3 billion Swiss francs ($2.8 billion)," said Karl-Heinz Koch, analyst at brokerage Helvea in Zurich. Roche is expected to file for approval in Europe and the U.S. in 2011. Report  

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.